Anticholinergic Burden and Cognitive Impairment in Nursing Homes: A Comparison of Four Anticholinergic Scales.
Journal
Drugs & aging
ISSN: 1179-1969
Titre abrégé: Drugs Aging
Pays: New Zealand
ID NLM: 9102074
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
accepted:
27
07
2023
medline:
26
10
2023
pubmed:
25
8
2023
entrez:
24
8
2023
Statut:
ppublish
Résumé
Medications with anticholinergic effects are commonly used in nursing homes, and their cumulative effect is of particular concern for the risk of adverse effects on cognition. The relation between cognitive function and anticholinergic burden measured with four scales, the Anticholinergic Cognitive Burden (ACB) Scale, the Anticholinergic Risk Scale, the German Anticholinergic Burden Scale, and the CRIDECO Anticholinergic Load Scale, is assessed according to the hypothesis that a higher anticholinergic burden is associated with reduced cognitive performance. This retrospective cross-sectional multicenter study was conducted in a sample of Italian long-term-care nursing homes (NH). Sociodemographic details, diagnosis, and drug treatments of each NH resident were collected using medical records four times during 2018 and 2019. Cognitive status was rated with the Mini-Mental State Examination (MMSE). The prevalence of anticholinergic use and its burden were calculated referring to the last time point for each patient. A longitudinal analysis was done on NH residents with at least two MMSE between 2018 and 2019 to assess the relation between the anticholinergic load and decline in MMSE. The relationship between drug-related anticholinergic burden and cognitive performance was analyzed using Poisson regression model theory. Multivariate analyses were adjusted according to the known risk factors of reduced cognitive performance available [age, sex, history of stroke or transient ischemic attack (TIA), and number of non-anticholinergic drugs] and for cholinesterase inhibitors. In view of the high number of subjects with an MMSE score = 0 among residents with dementia, for this group a zero-inflated Poisson regression model was used to give more consistent results. The association of anticholinergic burden with mortality was examined from each patient's last visit using a multivariate logistic model adjusted for age, sex, and Charlson Comorbidity Index (CCI). Among 1412 residents recruited, a clear direct relationship was found between higher anticholinergic burden and cognitive impairment only for the Anticholinergic Cognitive Burden Scale. Residents taking an anticholinergic who scored 5 or more had 2.5 points more decline than those not taking them (p < 0.001). Among residents without dementia there was a trend toward direct relationship for the Anticholinergic Cognitive Burden Scale and the Anticholinergic Risk Scale. Residents with higher scores had about 2 points more decline than residents not taking anticholinergic drugs. No relation was found between anticholinergic burden and cognitive decline or mortality. The cumulative effect of medications with modest antimuscarinic activity may influence the cognitive performance of NH residents. The anticholinergic burden measured with the ACB scale should help identify NH residents who may benefit from reducing the anticholinergic burden. A clear direct relationship between anticholinergic burden and cognitive impairment was found only for the ACB Scale.
Sections du résumé
BACKGROUND
Medications with anticholinergic effects are commonly used in nursing homes, and their cumulative effect is of particular concern for the risk of adverse effects on cognition.
OBJECTIVE
The relation between cognitive function and anticholinergic burden measured with four scales, the Anticholinergic Cognitive Burden (ACB) Scale, the Anticholinergic Risk Scale, the German Anticholinergic Burden Scale, and the CRIDECO Anticholinergic Load Scale, is assessed according to the hypothesis that a higher anticholinergic burden is associated with reduced cognitive performance.
METHODS
This retrospective cross-sectional multicenter study was conducted in a sample of Italian long-term-care nursing homes (NH). Sociodemographic details, diagnosis, and drug treatments of each NH resident were collected using medical records four times during 2018 and 2019. Cognitive status was rated with the Mini-Mental State Examination (MMSE). The prevalence of anticholinergic use and its burden were calculated referring to the last time point for each patient. A longitudinal analysis was done on NH residents with at least two MMSE between 2018 and 2019 to assess the relation between the anticholinergic load and decline in MMSE. The relationship between drug-related anticholinergic burden and cognitive performance was analyzed using Poisson regression model theory. Multivariate analyses were adjusted according to the known risk factors of reduced cognitive performance available [age, sex, history of stroke or transient ischemic attack (TIA), and number of non-anticholinergic drugs] and for cholinesterase inhibitors. In view of the high number of subjects with an MMSE score = 0 among residents with dementia, for this group a zero-inflated Poisson regression model was used to give more consistent results. The association of anticholinergic burden with mortality was examined from each patient's last visit using a multivariate logistic model adjusted for age, sex, and Charlson Comorbidity Index (CCI).
RESULTS
Among 1412 residents recruited, a clear direct relationship was found between higher anticholinergic burden and cognitive impairment only for the Anticholinergic Cognitive Burden Scale. Residents taking an anticholinergic who scored 5 or more had 2.5 points more decline than those not taking them (p < 0.001). Among residents without dementia there was a trend toward direct relationship for the Anticholinergic Cognitive Burden Scale and the Anticholinergic Risk Scale. Residents with higher scores had about 2 points more decline than residents not taking anticholinergic drugs. No relation was found between anticholinergic burden and cognitive decline or mortality.
CONCLUSIONS
The cumulative effect of medications with modest antimuscarinic activity may influence the cognitive performance of NH residents. The anticholinergic burden measured with the ACB scale should help identify NH residents who may benefit from reducing the anticholinergic burden. A clear direct relationship between anticholinergic burden and cognitive impairment was found only for the ACB Scale.
Identifiants
pubmed: 37620654
doi: 10.1007/s40266-023-01058-w
pii: 10.1007/s40266-023-01058-w
doi:
Substances chimiques
Cholinergic Antagonists
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1017-1026Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Kersten H, Wyller TB. Anticholinergic drug burden in older people’s brain—how well is it measured? Basic Clin Pharmacol Toxicol. 2014;114:151–9.
doi: 10.1111/bcpt.12140
pubmed: 24112192
Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015;15:31.
doi: 10.1186/s12877-015-0029-9
pubmed: 25879993
pmcid: 4377853
Cardwell K, Hughes CM, Ryan C. The association between anticholinergic medication burden and health related outcomes in the “oldest old”: a systematic review of the literature. Drugs Aging. 2015;32:835–48.
doi: 10.1007/s40266-015-0310-9
pubmed: 26442862
Welsh TJ, van der Wardt V, Ojo G, Gordon AL, Gladman JRF. Anticholinergic drug burden tools/scales and adverse outcomes in different clinical settings: a systematic review of reviews. Drugs Aging. 2018;35:523–38.
doi: 10.1007/s40266-018-0549-z
pubmed: 29736815
Fox C, Smith T, Maidment I, Chan W-Y, Bua N, Myint PK, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43:604–15.
doi: 10.1093/ageing/afu096
pubmed: 25038833
Egberts A, Moreno-Gonzalez R, Alan H, Ziere G, Mattace-Raso FUS. Anticholinergic drug burden and delirium: a systematic review. J Am Med Dir Assoc. 2021;22:65-73.e4.
doi: 10.1016/j.jamda.2020.04.019
pubmed: 32703688
Abrams P, Andersson K-E, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148:565–78.
doi: 10.1038/sj.bjp.0706780
pubmed: 16751797
pmcid: 1751864
Salahudeen MS, Chyou T-Y, Nishtala PS. Serum anticholinergic activity and cognitive and functional adverse outcomes in older people: a systematic review and meta-analysis of the literature. PLoS ONE. 2016;11: e0151084.
doi: 10.1371/journal.pone.0151084
pubmed: 26999286
pmcid: 4801377
Lisibach A, Benelli V, Ceppi MG, Waldner-Knogler K, Csajka C, Lutters M. Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review. Eur J Clin Pharmacol. 2021;77:147–62.
doi: 10.1007/s00228-020-02994-x
pubmed: 33011824
Brombo G, Bianchi L, Maietti E, Malacarne F, Corsonello A, Cherubini A, et al. Association of anticholinergic drug burden with cognitive and functional decline over time in older inpatients: results from the CRIME Project. Drugs Aging. 2018;35:917–24.
doi: 10.1007/s40266-018-0584-9
pubmed: 30191516
Durán CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol. 2013;69:1485–96.
doi: 10.1007/s00228-013-1499-3
pubmed: 23529548
Avorn J, Gurwitz JH. Drug use in the nursing home. Ann Intern Med. 1995;123:195–204.
doi: 10.7326/0003-4819-123-3-199508010-00007
pubmed: 7598302
Pasina L, Novella A, Cortesi L, Nobili A, Tettamanti M, Ianes A. Drug prescriptions in nursing home residents: an Italian multicenter observational study. Eur J Clin Pharmacol. 2020;76:1011–9.
doi: 10.1007/s00228-020-02871-7
pubmed: 32314001
Landi F, Dell’Aquila G, Collamati A, Martone AM, Zuliani G, Gasperini B, et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. J Am Med Dir Assoc. 2014;15:825–9.
doi: 10.1016/j.jamda.2014.08.002
pubmed: 25282629
Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4:311–20.
doi: 10.2217/1745509X.4.3.311
Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168:508–13.
doi: 10.1001/archinternmed.2007.106
pubmed: 18332297
Kiesel EK, Hopf YM, Drey M. An anticholinergic burden score for German prescribers: score development. BMC Geriatr. 2018;18:239.
doi: 10.1186/s12877-018-0929-6
pubmed: 30305048
pmcid: 6180424
Ramos H, Moreno L, Pérez-Tur J, Cháfer-Pericás C, García-Lluch G, Pardo J. CRIDECO Anticholinergic load scale: an updated anticholinergic burden scale. Comparison with the ACB scale in spanish individuals with subjective memory complaints. J Pers Med. 2022;12:207.
doi: 10.3390/jpm12020207
pubmed: 35207695
pmcid: 8876932
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. Tools for assessment of the appropriateness of prescribing and association with patient-related outcomes: a systematic review. Drugs Aging. 2018;35:43–60.
doi: 10.1007/s40266-018-0516-8
pubmed: 29350335
Ghibelli S, Marengoni A, Djade CD, Nobili A, Tettamanti M, Franchi C, et al. Prevention of inappropriate prescribing in hospitalized older patients using a computerized prescription support system (INTERcheck®). Drugs Aging. 2013;30:821–8.
doi: 10.1007/s40266-013-0109-5
pubmed: 23943248
Pasina L, Marengoni A, Ghibelli S, Suardi F, Djade CD, Nobili A, et al. A multicomponent intervention to optimize psychotropic drug prescription in elderly nursing home residents: an Italian multicenter, prospective, pilot study. Drugs Aging. 2016;33:143–9.
doi: 10.1007/s40266-015-0336-z
pubmed: 26689398
Morris JC, Edland S, Clark C, Galasko D, Koss E, Mohs R, et al. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer’s disease. Neurology. 1993;43:2457–65.
doi: 10.1212/WNL.43.12.2457
pubmed: 8255439
Teramura-Grönblad M, Raivio M, Savikko N, Muurinen S, Soini H, Suominen M, et al. Potentially severe drug-drug interactions among older people and associations in assisted living facilities in Finland: a cross-sectional study. Scand J Prim Health Care. 2016;34:250–7.
doi: 10.1080/02813432.2016.1207142
pubmed: 27428445
pmcid: 5036014
Hsu W-H, Wen Y-W, Chen L-K, Hsiao F-Y. Comparative associations between measures of anti-cholinergic burden and adverse clinical outcomes. Ann Fam Med. 2017;15:561–9.
doi: 10.1370/afm.2131
pubmed: 29133497
pmcid: 5683870
Ali S, Peterson GM, Bereznicki LR, Salahudeen MS. Association between anticholinergic drug burden and mortality in older people: a systematic review. Eur J Clin Pharmacol. 2020;76:319–35.
doi: 10.1007/s00228-019-02795-x
pubmed: 31832732
Patnode CD, Perdue LA, Rossom RC, Rushkin MC, Redmond N, Thomas RG, et al. Screening for cognitive impairment in older adults: an evidence update for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 [cited 2023 Jun 7]. http://www.ncbi.nlm.nih.gov/books/NBK554654/ . Accessed 23 Aug 2023.
Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59:1477–83.
doi: 10.1111/j.1532-5415.2011.03491.x
pubmed: 21707557
Pasina L, Lucca U, Tettamanti M. Relation between anticholinergic burden and cognitive impairment: results from the Monzino 80-plus population-based study. Pharmacoepidemiol Drug Saf. 2020;29:1696–702.
doi: 10.1002/pds.5159
pubmed: 33098318
Pasina L, Colzani L, Cortesi L, Tettamanti M, Zambon A, Nobili A, et al. Relation between delirium and anticholinergic drug burden in a cohort of hospitalized older patients: an observational study. Drugs Aging. 2019;36:85–91.
doi: 10.1007/s40266-018-0612-9
pubmed: 30484239
Pasina L, Djade CD, Lucca U, Nobili A, Tettamanti M, Franchi C, et al. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. Drugs Aging. 2013;30:103–12.
doi: 10.1007/s40266-012-0044-x
pubmed: 23239364
Pasina L, Rizzi B, Nobili A, Recchia A. Anticholinergic load and delirium in end-of-life patients. Eur J Clin Pharmacol. 2021;77:1419–24.
doi: 10.1007/s00228-021-03125-w
pubmed: 33733683
Kua C-H, Mak VSL, Huey Lee SW. Health outcomes of deprescribing interventions among older residents in nursing homes: a systematic review and meta-analysis. J Am Med Dir Assoc. 2019;20:362-372.e11.
doi: 10.1016/j.jamda.2018.10.026
pubmed: 30581126
Ailabouni N, Mangin D, Nishtala PS. DEFEAT-polypharmacy: deprescribing anticholinergic and sedative medicines feasibility trial in residential aged care facilities. Int J Clin Pharm. 2019;41:167–78.
doi: 10.1007/s11096-019-00784-9
pubmed: 30659492
Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167:781–7.
doi: 10.1001/archinte.167.8.781
pubmed: 17452540
Hilmer SN. Calculating and using the drug burden index score in research and practice. Expert Rev Clin Pharmacol. 2018;11:1053–5.
doi: 10.1080/17512433.2018.1528145
pubmed: 30269609